Then add JW or JZ if the drug came from single-dose containers, and sanity-check the unit count against the current MUE table before the claim goes out. To run the math — including the JW/JZ waste split and vial combinations — use the infusion billing units calculator.
A J-code price means nothing by itself. CMS prices every Part B drug per descriptor unit — the quarterly ASP file lists a payment limit for one unit, and the claim multiplies that limit by the units you report. The descriptor is the atomic quantity of the whole system. Get the descriptor wrong and every downstream number is wrong: the reimbursement, the patient's 20% coinsurance, the buy-and-bill margin math, all of it.
The unit is a billing convention, not a clinical one. Nobody administers “40 units” of infliximab; they administer 400 mg. The units field is where the clinical dose gets translated into the payer's currency, and that translation — one division and one round-up — is where a surprising share of drug-claim revenue is won or lost. The formula:
Every row below uses the actual HCPCS descriptor from the CMS Q2 2026 ASP pricing file — the same file this site's drug billing pages bind their prices to. Typical doses are illustrative (weight-based drugs vary by patient); the arithmetic is the point.
| Code | Drug | One unit = | Example dose | Units billed |
|---|---|---|---|---|
J1745 | Infliximab (Remicade) | 10 mg | 400 mg | 40 |
J2506 | Pegfilgrastim (Neulasta) | 0.5 mg | 6 mg | 12 |
J9312 | Rituximab (Rituxan) | 10 mg | 700 mg | 70 |
J9271 | Pembrolizumab (Keytruda) | 1 mg | 200 mg | 200 |
J2350 | Ocrelizumab (Ocrevus) | 1 mg | 600 mg | 600 |
J0178 | Aflibercept (Eylea) | 1 mg | 2 mg | 2 |
J1439 | Ferric carboxymaltose (Injectafer) | 1 mg | 750 mg | 750 |
J0897 | Denosumab | 1 mg | 120 mg | 120 |
Notice the spread: the “right” unit count for a routine dose runs from 2 to 750 depending entirely on how CMS wrote the descriptor. There's no pattern to memorize. Infliximab and rituximab happen to be 10 mg codes; pembrolizumab, ocrelizumab, and denosumab are 1 mg codes; pegfilgrastim is 0.5 mg. You look it up every time, from the current quarter's file — descriptors do change when codes are revised or replaced. (Or skip the lookup: the units calculator carries the current descriptors for the full drug library and does the dose→units→waste math in one pass.)
The Medicare Claims Processing Manual (Pub 100-04, Chapter 17) sets the convention: units are whole numbers, and when the administered dose falls between multiples of the descriptor amount, you round up to the next whole unit. A 45 mg dose of a 10 mg-per-unit drug is 4.5 → bill 5 units. The rounded-up fifth unit accounts for the partial 5 mg; you don't also report those same milligrams as waste on a JW line. One quantity of drug, one appearance on the claim.
Two edge cases worth pinning down:
Fractional units in the units field don't get partially paid; they get rejected or truncated depending on the clearinghouse. Whole numbers only.
The pharmacy pulled four 100 mg vials for a 350 mg dose. How many units go on the administered line? Whatever 350 mg works out to — the vial count never enters the calculation. Billing by vials-opened instead of dose-given systematically overbills whenever there's waste, and it's the exact error class payer audits are built to catch.
Where the leftover 50 mg goes depends on the container type:
CMS publishes Medically Unlikely Edits quarterly: for each HCPCS code, the maximum units of service one provider would plausibly report for one patient on one date of service. Drug-code MUEs are mostly derived from maximum labeled doses, so a correctly calculated unit count on a normal dose sits comfortably under the edit — and a dose-as-milligrams error blows through it by two or three orders of magnitude.
The edit's behavior depends on its MUE adjudication indicator (MAI):
The practical habit: any time a drug line's units exceed a few hundred, or a line denies with a units-related remark code, pull the current practitioner MUE table from CMS and compare before resubmitting. Resubmitting the same units into an MAI 2 edit is a waste of a cycle.
Claims that require NDC reporting carry two quantities for the same drug, in different units of measure, and they have to reconcile. The HCPCS units field counts descriptor increments. The NDC quantity reports the physical amount of the labeled product using the NDC unit-of-measure codes: UN (each), ML (milliliter), GR (gram), F2 (international unit), ME (milligram).
Concretely: 700 mg of rituximab at 10 mg/mL is 70 HCPCS units of J9312 (10 mg each) and an NDC quantity of 70 ML. The numbers happen to match there; they usually don't. The same 6 mg pegfilgrastim injection that bills 12 HCPCS units reports an NDC quantity of 0.6 ML for the prefilled syringe. Systems that copy one field into the other produce lines that fail the crosswalk.
State Medicaid programs have required NDC reporting on professional drug claims since the Deficit Reduction Act of 2005 tied it to manufacturer rebates, and a growing set of commercial payers require it too. If your claims touch Medicaid at all, the NDC quantity is not optional metadata — it's a denial vector with its own unit math. The medical-vs-pharmacy-benefit page covers where NDC-based billing takes over entirely.
| Error | What happens | The fix |
|---|---|---|
| Dose typed as units | Underpays silently when the descriptor is >1 mg (J1745: 400 “units” overbills 10×; 4 units underbills 10×). No denial fires on the underpay side. | Units audit on high-descriptor drugs: compare paid amounts per dose against the ASP file's per-unit limit × expected units. |
| Units exceed the MUE | Line denies; MAI 2 denials are unappealable, and resubmissions burn weeks. | Pre-submission MUE check on every drug line above a few hundred units. |
| Missing JW/JZ on single-dose containers | Claim returned as unprocessable — CMS edits have enforced the JW/JZ requirement since October 1, 2023. | Every single-dose-container claim carries exactly one of JW (waste line) or JZ (zero waste). |
| NDC quantity mismatch | Medicaid and NDC-requiring commercial lines reject when HCPCS units and NDC quantity don't reconcile through the concentration. | Crosswalk table per drug: descriptor amount, concentration, NDC unit of measure — maintained, not memorized. |
| Billing by vials opened | Overbills whenever waste exists; a favorite of post-payment audits because the MAR contradicts the claim. | Administered line = dose math only; waste goes on the JW line or nowhere. |
Divide the administered dose by the amount in the HCPCS descriptor and round up to the next whole unit. J1745 is defined per 10 mg, so 400 mg of infliximab bills as 40 units. The descriptor is the only denominator; vial and package sizes don't factor in.
Up, always — per Pub 100-04, Chapter 17. A 4.5-unit dose bills as 5 units; a dose smaller than one descriptor unit bills as 1. Fractional units get rejected, not partially paid.
40 units (400 mg ÷ 10 mg per unit). At the Q2 2026 payment limit of $31.04/unit that's $1,241.64 — billed as 4 units, the same infusion pays $124.16.
No — units follow the administered dose. Documented waste from single-dose containers goes on a separate JW line; zero-waste single-dose claims need JZ; multiple-dose-vial leftovers are never billable.
HCPCS units count descriptor increments; the NDC quantity reports the physical product amount in UN/ML/GR/F2/ME units of measure. Both appear on NDC-reporting claims and must reconcile through the drug's concentration.
The line denies or the claim returns, depending on the MUE adjudication indicator. MAI 2 edits are absolute; MAI 3 can be appealed with documentation. Check the quarterly CMS MUE table before resubmitting anything.
All sources are publicly available federal publications or paraphrased from trade-association educational materials. The methodology by which we resolve source disagreements is described in the Methodology.